Kornimate/medical-research-clean huggingface dataset:
examining persistence in smokers with schizophrenia

Conditions: Smoking Cessation; Schizophrenia; Schizo Affective Disorder

Summary: all participants will receive free weekly counseling (8- weeks) and free nicotine patches (10-weeks). they will complete assessment measures commonly used in smoking cessation studies. we hope to show that this treatment is feasible in this small pilot study before comparing it to a more established treatment in a future randomized clinical trial.

this study is a non-randomized trial of a new psychosocial treatment for smoking cessation (for smokers with schizophrenia) that is based on cognitive behavioral therapy for smoking cessation - a commonly used approach. participants will receive free weekly counseling (8- weeks) and free nicotine patches (10-weeks). they will complete assessment measures commonly used in smoking cessation studies. we hope to show that this treatment is feasible in this small pilot study before comparing it to a more established treatment in a future randomized clinical trial.

Eligibility criteria:
inclusion criteria: * must be between 18 - 64 years old * must indicate commitment to quitting smoking in the next 30 days * must smoke at least 5 cigarettes per day for past 6-months * expired breath carbon monoxide (co) \> 5 to ensure daily cigarette use * must score \< 8 (or \<7 for women) on the alcohol use disorders identification test * must score less than 3 on the 6-month drug abuse screening test-10 * must provide a negative urine drug screen for cannabis, cocaine, opiates, or * methamphetamine (note: participants with a positive screen for opiates may * participate with proof of prescription for opiates.) * must have a diagnosis of schizophrenia or schizoaffective disorder on structured clinical interview * psychiatric illness must be stable, as indicated by no hospitalizations in previous 8 weeks, and a stable psychotropic medication regimen including a stable antipsychotic dose for 8 weeks exclusion criteria: * must not be currently receiving tobacco dependence treatment counseling * must not currently be taking varenicline (chantix) * must not be taking bupropion (zyban/wellbutrin) to quit smoking * must not be taking any nicotine preparations (gum, lozenge, patch, spray, inhaler) daily over the last 10 days. * must not report unstable angina pectoris, myocardial infarction, or significant cardiac arrhythmia (including atrial fibrillation) in the past 90 days * must not be pregnant, breastfeeding, or planning on becoming pregnant in the next 4-months. women who can become pregnant may be included if using effective birth control * must not have pending legal matters with potential to result in jail time * must not be planning on moving outside local area in next 3-months
relationship between skeletal muscle mass and interventricular septum thickness in apparently healthy overweight and obese subjects

Conditions: Obesity

Summary: the study was aimed at investigating the relationship between skeletal muscle mass and interventricular septum thickness in overweight and obese subjects (bmi≥25)

subjects were enrolled at the first examination whether they were not taking any medication, including oral contraceptives or drugs for osteoporosis, and free of significant medical illnesses, except obesity. exclusion criteria were history of endocrinological diseases (diabetes mellitus, hypo or hyperthyroidism, hypopituitarism, etc.), chronic inflammatory diseases, stable known hypertension, angina pectoris, stroke, transient ischemic attack, heart infarction, congenital heart disease, malignancies, chronic inflammatory diseases, renal and liver failure, angina pectoris, myocardial infarction, heart failure, congenital heart diseases, minor and major stroke, and inherited thrombocytopenias and other major malignancies. subjects were examined by means of the medical history, hormonal, metabolic and routine hematochemical parameters. the investigators provided for a clinical baseline evaluation that included extemporaneous ambulatory blood pressure (bp), echocardiography, bioimpedance and a physical assessment of body weight, body mass index (bmi) and waist circumference (wc) as anthropometric parameters.

Eligibility criteria:
inclusion criteria: * overweight or obesity (bmi\> 25 kg/m2) exclusion criteria: * any kind of drug * hypertension * endocrine diseases (diabetes mellitus, hypo or hyperthyroidism, hypopituitarism, etc.), * chronic inflammatory diseases * renal failure * liver failure * angina pectoris * myocardial infarction and heart failure * genetic heart diseases * thrombocytopenias
effect of magnesium on remifentanil induced cough

Conditions: Cough

Summary: the hypothesis of this study is that magnesium sulfate pretreatment (50mg/kg) will reduce the incidence of cough and chest wall rigidity caused by remifentanil administration. the purpose of this study was to investigate the effect of magnesium sulfate administered before induction of anesthesia on thoracic stiffness and cough response caused by opioid analgesics administered for general anesthesia.


Eligibility criteria:
inclusion criteria: * patients aged 20-75 years of age who are undergoing surgery under general anesthesia using a laryngeal mask and who have consented to participate in this study among american society of anesthesiologists body grade 1 or 2 exclusion criteria: * when coughing may occur due to an underlying disease (upper respiratory infection, rhinitis, post nasal drip, asthma, chronic obstructive pulmonary disease, pneumonia, bronchitis, current smokers, etc.) * if you have kidney disease that can affect magnesium metabolism (glomerular filtration rate less than 60) * if you are taking opioid analgesics or magnesium for other reasons * patients with hypermagnesemia * patients with atrioventricular block (stages i-iii) or other cardiac conduction disorders * pregnant or lactating women * patients with myasthenia gravis * patients taking drugs that are contraindicated or interact with magnesium (barbitalates, aminoglycoside antibiotics, isoniazid, chlorpromazine, digoxin) * in case of hypersensitivity to magnesium * patients with a history of hypersensitivity to propofol and any of its components * patients with a history of hypersensitivity to remifentanil and other fentanyl analogues
99tc-mdp for thyroid-associated ophthalmopathy

Conditions: Thyroid-Associated Ophthalmopathy

Summary: to investigate the efficacy，safety and tolerability of 99tc-mdp in comparison to methylprednisolone, in the treatment of participants suffering from active moderate to severe tao.


Eligibility criteria:
inclusion criteria: * the patient age 18 years to 76 years; * fewer than 6 months from onset of tao; * clinical diagnosis of graves' disease associated with active tao and a clinical activity score of ≥ 3; * moderate to severe tao; * no previous medical or surgical treatment, excluding local supportive measures and oral steroids if the maximum cumulative dose is less than 1000 mg methylprednisolone or equivalent with at least 6 weeks between last administration of oral steroids and randomization. exclusion criteria: * optic neuropathy, severe orbital appearance and surgical; * extra-thyroid disease; * pregnant and children; * severe impairment of cardiac, hepatic and renal functions; * allergies; * other contraindications.

Keywords: 99tc-mdp tao efficacy safety
brazil nut consumption in microvascular endothelial function, oxidative stress and metabolic abnormalities

Conditions: Dyslipidemia; Oxidative Stress

Summary: the purpose this research is to check the effect of brazil nuts consumption in oxidative stress, metabolic abnormalities and microvascular endothelial function dyslipidemic and hypertensive patients.


Eligibility criteria:
inclusion criteria: * adults \> 20 years old * dyslipidemic * hypertensive exclusion criteria: * allergy to nuts * consumption of nuts or vitamins/minerals supplement * loss weight before the research * pregnancy * kidney chronic disease
association between pococyturia and pre-eclampsia severity

Conditions: Pre-Eclampsia

Summary: pre-eclampsia is an hypertensive disorder appearing during pregnancy, inducing serious maternal, fetal and neonatal mortality and morbidity. twenty four hours proteinuria is a key element to define pre-eclampsia severity but is delaying the result by 24 hours and constraining for the patient. a simple and rapid indicator for severe preeclampsia would help clinicians to make appropriate decision in patient management. we hypothesized that urinary podocyturia is correlated to preeclampsia severity. this is a prospective, non-interventional, monocentric study.


Eligibility criteria:
inclusion criteria: * women aged 18 years or more * single pregnancy * admission for pre-eclampsia * patient receiving information and non-opposition to participate exclusion criteria: * multiple pregnancy * in utero fetal demise excepted if associated with pre-eclampsia * antecedent of nephropathy * fetal malformation, chromosomal anomalies * inability to understand information provided * prisoner or under administrative supervision
a dose-ranging study of the efficacy of abt-894 in adults with attention-deficit/hyperactivity disorder (adhd)

Conditions: Attention-Deficit/Hyperactivity Disorder; ADHD

Summary: a dose-ranging study of the efficacy of abt-894 in adults with attention-deficit/hyperactivity disorder (adhd)


Eligibility criteria:
inclusion criteria: * meet criteria for attention-deficit/hyperactivity disorder * have voluntarily signed an informed form * are between 18 and 60 years of age * will use contraceptive methods during the study * women must not be pregnant or breast-feeding * must be in generally good health * are fluent in english exclusion criteria: * they have a current or past diagnosis of schizoaffective disorder, schizophrenia, obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic disorder or mental retardation * they have a current diagnosis of major depressive episode, generalized anxiety disorder (gad), or post-traumatic stress disorder (ptsd) or has a clinically significant sleep disorder requiring treatment * they require ongoing treatment or expected treatment with any psychotropic medication, including anxiolytics, antipsychotics, anticonvulsants, antidepressants, mood stabilizers, nicotine replacement therapies or varenicline * they require ongoing treatment or expected treatment with coumadin * they failed to respond to two or more adequate trials of fda-approved adhd medication * they have taken atomoxetine during the last 3 months * they have violent, homicidal or suicidal ideation * they have a significant history of medical diagnoses, seizure disorder, tourette's syndrome, traumatic brain injury, or a central nervous system (cns) disease, excluding adhd * they have a urine drug screen that is positive for alcohol or drugs of abuse * they have a history of substance or alcohol disorder during the last 3 months
a study to evaluate the efficacy, safety and tolerability of pdno infusion in covid-19 patients with acute pulmonary hypertension

Conditions: Pulmonary Hypertension; COVID-19

Summary: this is an open-label, multicentre study evaluating the effect, safety and tolerability of the two regioisomers 1-(nitrosooxy)propan-2-ol and 2-(nitrosooxy)propan-1-ol (pdno) infusion given to covid-19 patients with acute pulmonary hypertension (aph) and/or acute cor pulmonale (acp).


Eligibility criteria:
inclusion criteria: * ability to understand and willing to sign an icf * male and female patients at least 18 years of age * diagnosed with covid-19 at admission to the icu * diagnosed with echocardiographic signs of pulmonary artery systolic pressure (pasp) \> 40 mmhg exclusion criteria: * history of chronic pulmonary hypertension (ph), as judged by the investigator at screening * known new york heart association (nyha) functional class iii or iv symptoms * left heart failure with ejection fraction (ef) \< 35% * acute coronary syndrome * body mass index (bmi) \> 45 kg/m\^2 * estimated glomerular filtration rate (egfr) \< 30 ml/min * methb \> 3% * pco2 \> 7 * indication of liver disease, defined by serum levels of either alanine aminotransferase (alt), aspartate aminotransferase (ast) or alkaline phosphatase (alp) above 3 x upper limit of normal (uln) at screening * haemoglobin \< 80 g/dl * thrombocytopenia (platelet count \< 80000/mm\^3) * prothrombin time international ratio (inr) \> 1.4 * pregnancy, or a positive pregnancy test * ongoing daily treatment the last 3 days with non-steroidal anti-inflammatory drugs * known active malignancy within the past 3 years * history of allergy/hypersensitivity to pd or ongoing allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to pdno * history of any other clinically significant disease or disorder * participation in any interventional clinical study

Keywords: acute pulmonary hypertension
the effects of transcranial direct current stimulation on executive function in people with mild to moderate dementia

Conditions: Dementia; Executive Function; Transcranial Direct Current Stimulation

Summary: to study the effects of transcranial direct current stimulation on executive function in people with mild to moderate dementia

extensive research had shown executive dysfunction in people with dementia (pwd) is associated with functional abnormalities in prefrontal regions such as the right inferior frontal gyrus (right ifg) or the left dorsal lateral pre-frontal cortex (left dlpfc) . clinical studies suggest that tdcs may be a useful therapeutic tool. post-tdcs improvements have also been shown in visuo-motor coordination of healthy controls and performance in working memory. the aim of this study is to investigate the effect of tdcs stimulation over left dlpfc or right ifg on attention, inhibition and working memory and their neural correlates in people with dementia (pwd) and healthy controls (hc).this study is planned as a double-blinded, randomized case-control interventional study with a duration of 30 months.

Eligibility criteria:
inclusion criteria: * pwd must be aged at least 65 years or above when informed consent is obtained in the presence of his / her first degree relatives. * pwd must meet criteria of dsm-v for dementia as well as for historical diagnosis of dementia. * pwd must have a chinese moca score \> 19 (mild to moderate cognitive deficits) at screening. * subjects (both pwd and hc) must be physically healthy, and must be able to understand and be willing to sign the informed consent document exclusion criteria: * subject with major neurological illness. * subject with other diagnosed psychiatric disorders * subjects reported with history of substance abuse, which including alcohol, drugs or any medication which is indicative of chronic abuse. * failures to comply with the study protocol or to follow the instructions. * self-reported with known skin diseases or skin allergy history. * self-reported with metallic implants, dentures * self-reported with history of claustrophobia. (this is excluded because subject needs to stay in a quiet room with the head-mounted fnirs and tdcs, which may elicit their feeling of anxiety)
safety and pk of oral encochleated amphotericin b (camb/mat2203) for antifungal prophylaxis in patients undergoing induction chemotherapy for acute myelogenous and lymphoblastic leukaemia

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia

Summary: a non-randomized, prospective , multicenter, open uncontrolled study in patients with acute myelogenous (aml) or lymphoblastic leukaemia (all)

this is an open label phase ii clinical study to evaluate the safety and pharmacokinetics of oral encochleated amphotericin b (camb/mat2203) for prevention of invasive fungal infections in approximately 30 patients undergoing induction therapy for aml/all.

Eligibility criteria:
inclusion criteria: * newly diagnosed aml/all receiving chemotherapy inducing neutropenia \< 500 cells/mm3 * able to have all screening tests done to allow for study drug administration no later than 5 days after start of chemotherapy * sign informed consent * ≥ 18 years of age exclusion criteria: * known hypersensitivity to amphotericin b, specifically anaphylactic reaction * fungal induced fever (≥ 38°c) * proven, possible or probably invasive fungal infection in previous 12 months * serum galactomannan index (gmi)≥ 0.5 at screening * pulmonary infiltrates at screening * current treatment with amphotericin b * sever comorbidity other than underlying haematological disease * prolongation of corrected qt interval * history of convulsion * pregnant or breastfeeding * females of childbearing potential who do not practice sexual abstinence or who do not agree to use appropriate contraceptive methods * presence of hepatic disease * total bilirubin \> 3 x upper limit of normal * age-adjusted creatinine clearance \< 30 ml/minute * participating in any other clinical study
clinical sequencing project for metastatic cancer patients for personalized cancer clinic.

Conditions: Colorectal Cancer

Summary: the next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. the genome analysis needs systematic infra and database based on personal genetic information. therefore, a big data of genome-clinical information is important. to determine the feasibility of the use of tumor's molecular profiling and targeted therapies in the treatment of advanced cancer and to determine the clinical outcome(response rate,pfs, duration of response and overall survival )of patients with advanced cancer, the investigators are going to take a tumor tissue of patients and process molecular profiling and receive molecular profile directed treatments.


Eligibility criteria:
inclusion criteria: 1. subject is at least 19 years of age. 2. subject has a histologically or cytologically confirmed diagnosis of colorectal cancer. 3. prior treatment with anti-pdl1 antibody or immune check point inhibitor or ramucirumab therapy in the first-line or maintenance setting is allowed 4. they must have refractory or progressive disease for which there is no further curative therapy available. 5. be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy of the tissue sample quality for assessment of biomarker status. 6. must have a life expectancy of 3 months or more 7. written and voluntary informed consent understood, signed and dated. exclusion criteria: 1. patients who do not have enough tissue for acquisition
study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of velpatasvir in participants with chronic hcv infection

Conditions: Chronic Hepatitis C Virus

Summary: the primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly gs-5816) in hcv treatment naive participants with genotypes 1-6.


Eligibility criteria:
key inclusion criteria: * hcv treatment-naive adult participants (18-65 years of age) with chronic hcv infection and plasma hcv rna ≥ 5 log10 iu/ml at screening * agree to use protocol defined precautions against pregnancy key exclusion criteria: * chronic liver disease of a non-hcv etiology (e.g., hemochromatosis, wilson's disease, α1 antitrypsin deficiency, cholangitis) * evidence of cirrhosis * evidence of current drug abuse * screening laboratory results outside the protocol specified requirements note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: hepatitis c hcv genotype 1 genotype 2 genotype 3 genotype 4 genotype 5 genotype 6 liver disease
effect of empagliflozin on peritoneal and kidney function in end stage renal disease

Conditions: End Stage Renal Disease on Dialysis

Summary: the main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (esrd) on peritoneal dialysis. this is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic pd patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.

participants will undergo three study visits, and up to 4 safety visits, over 9 weeks. at 7 am in the first study visit, the participants will have taken 25mg empagliflozin once or matching placebo, thus producing peak plasma levels by 10 am. one week later the participant will return for the crossed over to the alternate study drug. at the conclusion of the 2nd study visit, all participants will be provided with empagliflozin 10mg tabs to be taken daily for 56 days (8 weeks). at each study visit and safety visit, participants will undergo a pet test.

Eligibility criteria:
inclusion criteria 1. patients actively undergoing pd with a reliably functioning pd catheter 2. stable peritoneal dialysis prescription 3. pd vintage \> 3 months 4. age \>18 years of age exclusion criteria: 1. history of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (er visit or ems response, glucagon administration or forced oral carbs) in the last 6 months 2. use of an sglt2 inhibitor within the prior 30 days 3. 1 or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter 4. anemia with hemoglobin \<8g/dl 5. inability to give written informed consent or follow study protocol 6. contraindication to receiving loop diuretics

Keywords: peritoneal dialysis
study to assess the efficacy and safety of act-541468 (daridorexant) in adult and elderly subjects with insomnia disorder

Conditions: Insomnia Disorder

Summary: the main purpose of this study is to assess efficacy and safety of act-541468 (daridorexant) in adult and elderly subjects with insomnia disorder. efficacy will be evaluated on objective and subjective sleep parameters.


Eligibility criteria:
inclusion criteria: * signed informed consent prior to any study-mandated procedure; * male or female aged ≥ 18 years; * insomnia disorder according to dsm-5 criteria; * insomnia severity index score ≥ 15; * insufficient sleep quantity as collected subjectively in the sleep diary; * women of childbearing potential must have a negative and urine pregnancy test and use the contraception scheme up to at least 30 days after last study treatment intake. exclusion criteria: * body mass index below 18.5 or above 40.0 kg/m2; * any lifetime history of of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (rem) behavior disorder, narcolepsy, or apnea/ hypopnea; * cognitive behavioral therapy (cbt) only allowed if, the treatment started at least 1 month prior to visit 3 and the subject agrees to continue this cbt throughout the study; * self-reported usual daytime napping ≥ 1 hour per day and ≥ 3 days per week; * acute or unstable psychiatric conditions diagnosed by the mini international neuropsychiatric interview; * mini mental state examination (mmse) score \< 25 in subjects ≥ 50 years; * for female subjects: pregnant, lactating or planning to become pregnant during projected duration of the study; * history or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments. * any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.